November 15-16, 2017 | Philadelphia, PA
A recent Drug Channels blog post focused on a QuintilesIMS report, discussing how the total value of pharmaceutical manufacturers’ off-invoice discounts, rebates, and other price concessions has more than doubled over the past five years, from $59 billion 2012 to an astonishing $127 billion in 2016.
What is the best way to position your organization to manage this increase? How are your colleagues from across the industry achieving success? Find out at CBI’s GTN Summit! Drug Channels readers will save $400 off of the standard registration rate when they use discount code SDP676.*
The 7th annual meeting covers a broad range of subjects related to strategic GTN forecasting, accounting estimates, data analytics and financial reporting specifically for life science companies. Some hot topics will be addressed, such as health care reform, GTN impacts of coupons and copay programs, revenue recognition based on the new standard, pipeline reserve accruals and much more! There are also session breakouts specifically for Pharma/Established Brands, Generics and Emerging Biotech/New Launch.
- Redefining Gross-to-Net – Moving Beyond Theory for Profitability, Streamlined Data, Organizational Transparency and Control
- Business Process Excellence – Instituting Best in Class Processes, Communication Flows and Data Frameworks for GTN
- Talent, Leadership and Organization Design – Prioritizing GTN
- Beyond Excel — GTN Data, Technology and Documentation: Sound-Off, Size-Up and Scale with Various Approaches to Systems and Automation
- Profitability and Managed Markets Strategy
- Inventory and Channel Forecasting
- Robotics and Artificial Intelligence in GTN
- Internal Controls and SOX Compliance
- Accounting and Reporting
- Financial Planning and Analytics
- Contract Strategy and Operations
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rate or non-profit rates. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.